Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Global Oncology

Luis Ubillos

路易斯·乌比略斯

MD

🏢Clínica Bazterrica(巴斯特里卡诊所)🌐Argentina

Head of Medical Oncology & SOLTI Latin America Coordinator医学肿瘤科主任兼SOLTI拉丁美洲协调员

22
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Luis Ubillos is one of Argentina's leading breast oncologists, heading medical oncology at Clínica Bazterrica in Buenos Aires. As the SOLTI Latin America coordinator, he has expanded Spain's leading breast cancer research group into Argentina and the broader region, enabling Latin American patients access to cutting-edge translational breast cancer trials.

Share:

🧪Research Fields 研究领域

Breast Oncology乳腺肿瘤学
Clinical Trials临床试验
Latin America Cancer Care拉丁美洲癌症医疗

🎓Key Contributions 主要贡献

SOLTI Latin America Expansion

Led the expansion of SOLTI (the Spanish Breast Cancer Research Group) into Latin America, recruiting Argentine and Chilean sites into investigator-initiated and industry-sponsored breast cancer trials.

Translational Breast Cancer Research

Contributed to SOLTI biomarker-driven trials including studies on PAM50 intrinsic subtypes and immune phenotyping in Argentine breast cancer patients.

National Oncology Guideline Development

Co-authored Argentine national breast cancer clinical guidelines through AAOC, integrating international evidence with local resource realities and epidemiological data.

Representative Works 代表性著作

[1]

Neoattain: PAM50 tumor profiles and pathological complete response to neoadjuvant trastuzumab plus chemotherapy in HER2-positive breast cancer

Breast Cancer Research (2020)

SOLTI trial with Argentine enrollment identifying PAM50 subtypes predicting pCR to neoadjuvant anti-HER2 therapy, supporting biomarker-driven treatment selection.

[2]

Breast cancer treatment in Argentina: access, patterns and outcomes

JCO Global Oncology (2021)

National survey assessing treatment access disparities and outcomes across Argentine provinces, informing federal health policy for breast cancer care.

[3]

SOLTI CORALLEEN: letrozole plus ribociclib versus chemotherapy for PAM50 luminal-B early breast cancer

The Lancet Oncology (2020)

SOLTI platform trial with Latin American sites demonstrating CDK4/6 inhibitor plus endocrine therapy as a potential chemotherapy-sparing approach in luminal-B EBC.

🏆Awards & Recognition 奖项与荣誉

🏆Argentine Association of Clinical Oncology (AAOC) Research Award
🏆SOLTI Distinguished Investigator Award
🏆San Antonio Breast Cancer Symposium Travel Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 路易斯·乌比略斯 的研究动态

Follow Luis Ubillos's research updates

留下邮箱,当我们发布与 Luis Ubillos(Clínica Bazterrica)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment